FDA Proposed Rule On PET Drug Manufacturing Expected This Month
This article was originally published in The Pink Sheet Daily
Executive Summary
Proposed current good manufacturing practices requirements for positron emission tomography drugs will reflect the “unique characteristics” of radiopharmaceuticals, HHS says. The rule would build upon a draft guidance and preliminary draft proposed cGMP rule, both issued in 2002.
You may also be interested in...
PET Drug Proposed Rule Clears OMB
FDA's proposed rule on current good manufacturing practices for positron emission tomography drugs is headed for publication in the Federal Register following clearance by the Office of Management & Budget Aug. 30
PET Drug Proposed Rule Clears OMB
FDA's proposed rule on current good manufacturing practices for positron emission tomography drugs is headed for publication in the Federal Register following clearance by the Office of Management & Budget Aug. 30
GMP Oversight To Get FDA-Wide Coordination Under New Cmte.
The Council on Pharmaceutical Quality will oversee implementation of the initiative, which covers aseptic processing, quality systems, computerized systems in clinical trials, process analytical technologies and combination products.